公司资料
Nuvalent 股价、新闻与催化剂
- 股票代码:
- NUVL
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
123.96 USD (+0.02%)
收盘价
最后更新: 2026年7月14日
7.22B USD
市值
股价为何变动
Current closing-price context is not available for NUVL.
公司概览
业务概览
Nuvalent is a precision-oncology company developing next-generation kinase inhibitors for genetically defined cancers.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Nuvalent sits in targeted oncology biotechnology.
商业模式特征
The company depends on differentiated clinical data, molecule design, and the possibility of building best-in-class oncology assets.
生物医药行业定位
Nuvalent is a high-quality targeted-therapy name whose stock reacts quickly to efficacy and safety differentiation.
未来催化剂
- Nuvalent's catalysts are NVL-655 in ALK and NVL-520 in ROS1, where selectivity and tolerability data decide whether the next-gen kinase story keeps its premium. The company still needs each update to reinforce its differentiation.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。